Information for the public

Tafamidis (Vyndaqel) is not normally available on the NHS for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.

Your doctor should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your doctor decide when best to stop.

Information and support

These organisations can give you advice and support:

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4129-2

This page was last updated: